n°178

January 2017

Issue Contents
Editorial

Free  Out of the frying pan, into the fire

p.4
The case of olaparib

Marketing Authorisations

RTS,S/AS01E malaria vaccine (Mosquirix°)

p.5-8
Children living in malaria-endemic regions: little efficacy, poorly documented harms

Olaparib (Lynparza°)

p.9-12
Ovarian cancer: spare patients who are in remission

INN Common stem: -relin

p.12

Edoxaban (Lixiana°)

p.13-14
A third factor Xa inhibitor anticoagulant: no proven advantages

Sonidegib (Odomzo°) and extensive basal cell carcinoma

p.14-15
A vismodegib me-too

Adverse Effects

Benzodiazepines: dementia in the elderly?

p.16-17
Uncertainties should prompt cautious use

Statins: increased risk of type 2 diabetes

p.18-19
To be taken into account

Keppra° oral solutions of levetiracetam: cases of overdose

p.19
High-risk product line

Free  Pseudoephedrine: ischaemic colitis

p.20
Do not use nasal decongestants

Free  Sofosbuvir: pulmonary arterial hypertension?

p.20
Adverse reactions to this drug should be reported

Reviews

Hypertension

p.21-22
Targeting 120 mmHg: survival benefit after 3 years, but high renal risk

Outlook

Taking missing data into account in everyday practice

p.23-27
Impact on the harm-benefit balance of medical interventions

Masthead

Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe